#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4498	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2227	582.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1478	1478	C	665	C	565	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7250	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3928	552.1	0	.	n	.	0	T695C	SNP	695	695	T	1226	1226	C	545	C,A	460,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7250	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3928	552.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1868	1868	A	605	A,G	539,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7250	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3928	552.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2502	2502	C	686	C,T	593,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7250	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3928	552.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3128	3128	T	635	T,C	551,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7250	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3928	552.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2576	2576	A	710	A	622	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	602	folP	852	852	100.0	folP.l15.c4.ctg.1	2070	87.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1306	1308	AGC	144;144;143	A;G;C	120;124;120	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1386	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3795	109.4	1	SNP	p	S91F	0	.	.	271	273	TCC	789	791	TCC	113;113;114	T;C;C	101;97;102	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1386	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3795	109.4	1	SNP	p	D95G	0	.	.	283	285	GAC	801	803	GAC	114;114;114	G,A;A;C	98,1;97;98	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1386	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3795	109.4	1	SNP	p	D95N	0	.	.	283	285	GAC	801	803	GAC	114;114;114	G,A;A;C	98,1;97;98	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	528	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1708	92.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	575	577	ACC	141;142;141	A,C;C;C	121,1;120;121	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	528	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1708	92.2	0	.	p	.	0	R44H	NONSYN	130	132	CGC	590	592	CAC	140;141;141	C;A;C	119;118;118	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	528	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1708	92.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	773	775	CAC	148;147;146	C,A;A,T;C	127,1;128,1;131	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	528	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1708	92.2	1	SNP	p	G45D	0	.	.	133	135	GGC	593	595	GGC	140;140;140	G;G;C	121;118;119	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	362	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1403	77.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1464	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	128.2	1	SNP	p	D86N	0	.	.	256	258	GAC	850	852	GAC	175;174;174	G;A;C	143;139;148	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1464	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	128.2	1	SNP	p	S87R	0	.	.	259	261	AGT	853	855	AGT	174;173;173	A;G;T	149;146;143	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1464	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	128.2	1	SNP	p	S87I	0	.	.	259	261	AGT	853	855	AGT	174;173;173	A;G;T	149;146;143	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1464	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	128.2	1	SNP	p	S87W	0	.	.	259	261	AGT	853	855	AGT	174;173;173	A;G;T	149;146;143	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1464	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3422	128.2	1	SNP	p	S88P	0	.	.	262	264	TCC	856	858	TCC	173;171;172	T;C;C	146;148;152	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1224	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3004	121.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1789	1791	GGC	156;154;154	G;G,T;C	130;129,1;129	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1529	1531	GCA	164;164;162	G;C,A;A,C	138;139,1;141,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1532	1534	ATC	163;163;165	A;T,C;C	139;139,1;144	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1544	1546	GTG	162;161;159	G,C;T;G	137,1;134;139	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1544	1546	GTG	162;161;159	G,C;T;G	137,1;134;139	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2048	2050	ACC	100;100;102	A;C;C	91;90;93	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2102	2104	GCG	99;99;99	G;C;G	86;78;82	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2102	2104	GCG	99;99;99	G;C;G	86;78;82	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2225	2227	GGC	91;92;92	G;G;C	79;83;82	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2234	2236	GGC	93;93;92	G;G;C	82;79;79	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	970	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2883	100.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2252	2254	CCG	99;99;98	C;C;G	86;85;82	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1378	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3438	120.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1806	1808	CTG	142;143;143	C,G;T;G	115,2;119;113	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	694	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2290	90.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	812	812	C	116	C	102	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	319	90.74	porB1a.l15.c4.ctg.1	1521	13.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1226	1228	AAT	6;6;6	A;A;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	319	90.74	porB1a.l15.c4.ctg.1	1521	13.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1229	1231	AAT	6;6;6	A;A;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	319	90.74	porB1a.l15.c4.ctg.1	1521	13.4	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1241	1243	GTT	6;6;6	G;T;T	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	319	90.74	porB1a.l15.c4.ctg.1	1521	13.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1253	1255	GCA	6;6;6	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	319	90.74	porB1a.l15.c4.ctg.1	1521	13.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1276	1278	GTA	5;5;5	G;T;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	70	porB1a	984	319	90.74	porB1a.l15.c4.ctg.1	1521	13.4	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1288	1288	G	5	G	4	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	529	531	GGA	163;165;165	G;G;A	137;136;136	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	G50N	NONSYN	148	150	GGC	535	537	AAC	162;161;161	A;A;C	137;137;136	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	G129D	NONSYN	385	387	GGC	772	774	GAC	140;138;138	G;A;C	125;123;123	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	790	792	CTT	142;142;141	C;T;T	128;127;128	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	814	816	GGA	146;146;146	G;G;A	131;132;133	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	D171G	NONSYN	511	513	GAT	898	900	GGT	157;158;159	G,A;G;T	139,1;141;138	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	952	954	AGC	167;168;166	A;G;C	141;147;145	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1018	1018	T	174	T	150	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	1	SNP	p	G120K	0	.	.	358	360	GGT	745	747	GGT	143;143;142	G;G,C;T,A	127;127,1;128,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	1	SNP	p	A121D	0	.	.	361	363	GCC	748	750	GCC	142;139;137	G,T;C;C	124,1;123;126	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	828	porB1b	1035	1035	95.54	porB1b.l15.c30.ctg.1	1810	133.6	1	SNP	p	A121N	0	.	.	361	363	GCC	748	750	GCC	142;139;137	G,T;C;C	124,1;123;126	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2788	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5265	158.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2183	2185	AAT	170;169;168	A,C;A;T,G	146,1;137;139,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	394	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1531	77.2	1	SNP	p	V57M	1	.	.	169	171	ATG	796	798	ATG	157;157;157	A;T;G	136;126;134	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
